

APC-PCI Complex specific antibody
Mouse monoclonal antibody

Subclass: IgG1/k

CAT. NO.

JST 001-38

Clone: M3

SPECIFICITY JST 001-38 is specific for APC:PCI complex and cleaved PCI but has little reactivity towards native PCI. The dissociation constants (as determined by standard surface plasmon resonance technique) are: $K_d = 4 \times 10^{-10}$ M for PCI in complex with APC and 2×10^{-10} M for cleaved PCI. The value of K_d for native PCI is too low to measure, i.e., $\geq 10^{-5}$ M.

IMMUNOGEN Mixture of PCI in complex with PSA (approx. 80%) and PCI cleaved from such a complex (approx. 20%).

TESTED APPLICATIONS ELISA, WB (Not applicable)

SPECIES REACTIVITY (POSITIVE) Human

SPECIES REACTIVITY (NEGATIVE) Not determined

EPITOPE SPECIFICITY The epitope is located in the calcium-binding N-terminal EGF domain of protein C.

PRESENTATION

Content: Available in 400 μ L and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.

Preparation: Protein-A purified

Form: Liquid

Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide

Storage: 4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION **ELISA:** JST 001-38 shows excellent reactivity towards PCI in cleaved and complex form in ELISA. JST 001-38 is a part of the APC-PCI Matched Reagent Set and can be used in ELISA as a capture antibody in combination with SA001RA as the detection antibody (1-5).

WB: JST 001-38 shows low reactivity against denatured antigen in SDS-PAGE.

TARGET Activated Protein C (APC), a serine proteinase is inhibited by Protein C inhibitor (PCI). PCI belongs to a group of inhibitors sometimes referred to as serpins (serine proteinase inhibitors), and form 1:1 complexes with APC. PCI plasma concentration is approximately 4ug/ml. The complex formation between APC and PCI proceeds at a slow rate, which is manifested by a long half-life for APC in plasma, wherein $t_{1/2}$ is about 20 min. However, the rate of complex formation between APC and PCI is increased by heparin. Upon complex formation with APC, the serpin is cleaved in its so-called bait region, whereby a stable intermediate acyl complex is formed. With time, the intermediate acyl complex dissociates, whereby APC is regenerated and a proteolytically modified, i. e. cleaved, inactive serine proteinase inhibitor is formed.

REFERENCES

1. Strandberg K, Astermark J, Björgell O, Becker C, Nilsson PE, Stenflo J (2001) Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. *Thromb Haemost* 86:1400-08.
2. Bremme K, Hamad R, Berg E, Strandberg K, Stenflo J (2012) The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives. *Thromb Res*.130:636-9.
3. Elf JL, Strandberg K, Svensson PJ (2010) The diagnostic performance of APC-PCI complex determination compared to D-dimer in the diagnosis of deep vein thrombosis. *J Thromb Thrombolysis*. 29:465-70.
4. Bhiladvala P, Strandberg K, Stenflo J, Holm J (2006) Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex. *Thromb Res* 118:213-19.
5. Heslet L, Hald R, Recke C, Bangert K, Uttenthal LO (2008) Activated protein C-protein C inhibitor (APC-PCI) complex as a prognostic marker in sepsis. Presented at the The International Sepsis Forum (ISF) 2008, Granada, Spain.

CONDITIONS

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.

BioPorto Diagnostics A/S • Tuborg Havnevej 15, st. • DK-2900 Hellerup • Denmark • info@bioporto.com

www.bioporto.com • Phone: +45 4529 0000 • Fax: +45 4529 0001 • CVR/VAT: DK-1864 5882